Latest in AIMS Psilocybin Right-To-Try Effort

Latest in AIMS Psilocybin Right-To-Try EffortWe have taken an additional step recently in our effort to secure psilocybin therapeutic use for two of our cancer patients under State and Federal Right to Try (RTT) laws. On Monday 3/8/21, on behalf of AIMS Institute and Dr. Aggarwal, lawyers filed a petition for review in U.S. Ninth Circuit Court of Appeals of the DEA’s written decision last month to deny our request for RTT access to psilocybin from a duly licensed producer.

Below is the press release that went out and links to some news stories that have appeared.

We are looking for leading organizations committed to protecting the rights of seriously ill patients to have immediate access to safe use of psychedelic-assisted therapy to file ‘friend of the court’ amicus briefs in the case. Please get in touch if your organization or one you know of is interested in lending their voice of support to help our patients receive therapeutic access to the eligible investigational drug psilocybin under right to try. We have a great opportunity here to help advance this very needed therapeutic modality in contemporary hospice and palliative care. Patients treated by palliative care and mental health specialists in Canada have already been able to avail fungal psilocybin-assisted therapy legally under Canadian government exemptions for the past 7 months, and it has been very beneficial in palliation of existential and other distress by all reports.

Press Release: NATION’S FIRST LEGAL CHALLENGE TO ALLOW PSILOCYBIN THERAPY IN END-OF-LIFE CARE UNDER “RIGHT-TO-TRY” LAWS MOVES FORWARD
https://goteamtbg.com/dying-patients-need-access-to-psilocybin-for-anxiety-and-depression-relief/

Oregon Public Broadcasting: Physicians ask DEA to rethink ban on psilocybin
https://www.opb.org/article/2021/03/09/physicians-ask-dea-to-rethink-ban-on-psilocybin/

Marijuana Moment: DEA Sued By Doctor Who Wants Permission To Give Psilocybin Mushrooms To Patients
https://www.marijuanamoment.net/dea-sued-by-therapists-who-want-permission-to-give-psilocybin-mushrooms-to-patients/

Clinician, Patients Take the Fight for Psilocybin To Court
https://www.psychiatrictimes.com/view/clinician-patients-take-fight-psilocybin-to-court

Why Dying Patients Are Suing for Access to Magic Mushrooms
https://today.westlaw.com/Document/Icf70e0e081e411eb835ee9025e2233da/View/FullText.html?transitionType=Default&contextData=(sc.Default)&VR=3.0&RS=cblt1.0

Seattle Doctor, Lawyer Speak Out on Landmark DEA Psilocybin Lawsuit
truffle.report/seattle-doctor-lawyer-speak-out-on-landmark-dea-psilocybin-lawsuit/

Seattle Doctor, Lawyer Speak Out on Landmark DEA Psilocybin Lawsuit
truffle.report/seattle-doctor-lawyer-speak-out-on-landmark-dea-psilocybin-lawsuit/

Suing the DEA for Access to Psilocybin
https://www.mushroomrevival.com/blogs/podcast/suing-the-dea-for-access-to-psilocybin?fbclid=IwAR1QLWYCMjISeWOdoHQVqlb1PaI1iA8NvsSgh7rut71VqZDQpAjU089fUBstruffle.report/seattle-doctor-lawyer-speak-out-on-landmark-dea-psilocybin-lawsuit/

 

Latest Blog Posts

Stellate Ganglion Block Effectiveness for PTSD, Anxiety, and Depression in Psychiatric Outpatients: A Retrospective Analysis

Stellate Ganglion Block Effectiveness for PTSD, Anxiety, and Depression in Psychiatric Outpatients: A Retrospective Analysis

https://scholarworks.seattleu.edu/dnp-projects/166/ The prevalences of Post-Traumatic Stress Disorder (PTSD), generalized anxiety disorder (GAD), and major depressive disorder (MDD) have risen significantly in recent years, particularly following the COVID-19 pandemic. Many individuals remain symptomatic despite conventional treatments, highlighting the need for novel, integrative interventions. Stellate Ganglion Block (SGB), a procedure targeting the cervical sympathetic chain to modulate the autonomic nervous system, has emerged as a promising therapy for treatment-resistant psychiatric symptoms. Evaluating data from the PTSD Checklist for DSM-5 (PCL-5), Generalized Anxiety Disorder-7 (GAD-7), and Patient Health Questionnaire-9 (PHQ-9), this retrospective study examined the clinical outcomes of PTSD, anxiety, and depression symptoms ...

Read More
BEWARE OF CANCER MISINFORMATION

BEWARE OF CANCER MISINFORMATION

Our AIMS Institute oncology team is well informed about alternative cancer therapies such as ivermectin, intravenous vitamin C, mistletoe, curcumin, and mebendazole.  We help our patients sort through marketing hype, wishful thinking, and the real value of some alternative treatments. We say to our cancer patients who do not trust conventional medicine to beware of misinformation on the internet.  Be discerning.  We can help. Here is a recent MEDSCAPE article on this topic. ...

Read More
AIMS INSTITUTE’S COGNITIVE DECLINE PROTOCOL

AIMS INSTITUTE’S COGNITIVE DECLINE PROTOCOL

LJ STANDISH AND DAVID JAMES Dr. Standish and her team can help improve brain function, improve memory and slow cognitive decline in Alzheimer’s disease.  Please make an appointment to start.  Call 206-420-1321.  Scientific Rationale A protocol incorporating low-dose lithium orotate, Lion’s Mane mushroom extract, NADH, transcranial magnetic stimulation (TMS), and blood sugar regulation counseling is scientifically rational for treating cognitive decline based on mechanistic, preclinical, and emerging human studies. Low-Dose Lithium Orotate (5 mg/day) Recent brain tissue studies link low brain lithium to the onset and progression of Alzheimer’s disease, with deficiency accelerating synaptic loss and cognitive decline. Low-dose lithium orotate has ...

Read More
Call Us Text Us
Skip to content